Preclinical studies of the CaTeVac oncology vaccine have been completed in Russia. It is proposed to start using it in 2027, reported the Office of the Deputy Prime Minister of the Russian Federation Golikova. The development aims to train the patient's immune system to recognize and destroy tumor cells. In the future, the product may be used to treat melanoma, kidney cancer, primary tumors of the central nervous system and malignant solid tumors that have been exhausted by standard treatment. We are at MAX.